Literature DB >> 14656720

Structural characterization, tissue distribution, and functional expression of murine aminoacylase III.

Alexander Pushkin1, Gerardo Carpenito, Natalia Abuladze, Debra Newman, Vladimir Tsuprun, Sergey Ryazantsev, Srilakshmi Motemoturu, Pakan Sassani, Nadezhda Solovieva, Ramnath Dukkipati, Ira Kurtz.   

Abstract

Many xenobiotics are detoxified through the mercapturate metabolic pathway. The final product of the pathway, mercapturic acids (N-acetylcysteine S-conjugates), are secreted predominantly by renal proximal tubules. Mercapturic acids may undergo a transformation mediated by aminoacylases and cysteine S-conjugate beta-lyases that leads to nephrotoxic reactive thiol formation. The deacetylation of cysteine S-conjugates of N-acyl aromatic amino acids is thought to be mediated by an aminoacylase whose molecular identity has not been determined. In the present study, we cloned aminoacylase III, which likely mediates this process in vivo, and characterized its function and structure. The enzyme consists of 318 amino acids and has a molecular mass (determined by SDS-PAGE) of approximately 35 kDa. Under nondenaturing conditions, the molecular mass of the enzyme is approximately 140 kDa as determined by size-exclusion chromatography, which suggests that it is a tetramer. In agreement with this hypothesis, transmission electron microscopy and image analysis of aminoacylase III showed that the monomers of the enzyme are arranged with a fourfold rotational symmetry. Northern analysis demonstrated an approximately 1.4-kb transcript that was expressed predominantly in kidney and showed less expression in liver, heart, small intestine, brain, lung, testis, and stomach. In kidney, aminoacylase III was immunolocalized predominantly to the apical domain of S1 proximal tubules and the cytoplasm of S2 and S3 proximal tubules. The data suggest that in kidney proximal tubules, aminoacylase III plays an important role in deacetylating mercapturic acids. The predominant cytoplasmic localization of aminoacylase III may explain the greater sensitivity of the proximal straight tubule to the nephrotoxicity of mercapturic acids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656720     DOI: 10.1152/ajpcell.00192.2003

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  15 in total

1.  Structures of aminoacylase 3 in complex with acetylated substrates.

Authors:  Jennifer M Hsieh; Kirill Tsirulnikov; Michael R Sawaya; Nathaniel Magilnick; Natalia Abuladze; Ira Kurtz; Jeff Abramson; Alexander Pushkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 2.  Pharmacogenomics of hypertension and heart disease.

Authors:  Meghan J Arwood; Larisa H Cavallari; Julio D Duarte
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

3.  Inhibition of aminoacylase 3 protects rat brain cortex neuronal cells from the toxicity of 4-hydroxy-2-nonenal mercapturate and 4-hydroxy-2-nonenal.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Anatol Bragin; Kym Faull; Duilio Cascio; Robert Damoiseaux; Matthew J Schibler; Alexander Pushkin
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-20       Impact factor: 4.219

4.  Differential aminoacylase expression in neuroblastoma.

Authors:  Patrick M Long; Holly M Stradecki; Jane E Minturn; Umadevi V Wesley; Diane M Jaworski
Journal:  Int J Cancer       Date:  2011-04-01       Impact factor: 7.396

5.  Aminoacylase 3 binds to and cleaves the N-terminus of the hepatitis C virus core protein.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Ritu Vahi; Huma Hasnain; Martin Phillips; Christopher M Ryan; Ivo Atanasov; Kym F Faull; Ira Kurtz; Alexander Pushkin
Journal:  FEBS Lett       Date:  2012-09-22       Impact factor: 4.124

6.  Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design.

Authors:  Marja-Liisa Nuotio; Heini Sánez Tähtisalo; Alexandra Lahtinen; Kati Donner; Frej Fyhrquist; Markus Perola; Kimmo K Kontula; Timo P Hiltunen
Journal:  Epigenetics       Date:  2022-02-25       Impact factor: 4.861

7.  Transport of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, a metabolite of trichloroethylene, by mouse multidrug resistance associated protein 2 (Mrp2).

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Myong-Chul Koag; Debra Newman; Karoline Scholz; Galyna Bondar; Quansheng Zhu; Nuraly K Avliyakulov; Wolfgang Dekant; Kym Faull; Ira Kurtz; Alexander Pushkin
Journal:  Toxicol Appl Pharmacol       Date:  2010-01-06       Impact factor: 4.219

8.  Mouse aminoacylase 3: a metalloenzyme activated by cobalt and nickel.

Authors:  Kirill Tsirulnikov; Natalia Abuladze; Debra Newman; Sergey Ryazantsev; Talya Wolak; Nathaniel Magilnick; Myong-Chul Koag; Ira Kurtz; Alexander Pushkin
Journal:  Biochim Biophys Acta       Date:  2009-04-09

9.  Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.

Authors:  Timo P Hiltunen; Kati M Donner; Antti-Pekka Sarin; Janna Saarela; Samuli Ripatti; Arlene B Chapman; John G Gums; Yan Gong; Rhonda M Cooper-DeHoff; Francesca Frau; Valeria Glorioso; Roberta Zaninello; Erika Salvi; Nicola Glorioso; Eric Boerwinkle; Stephen T Turner; Julie A Johnson; Kimmo K Kontula
Journal:  J Am Heart Assoc       Date:  2015-01-26       Impact factor: 5.501

10.  Albuminuria is associated with too few glomeruli and too much testosterone.

Authors:  David A Long; Maria Kolatsi-Joannou; Karen L Price; Cecile Dessapt-Baradez; Jennifer L Huang; Eugenia Papakrivopoulou; Mike Hubank; Ron Korstanje; Luigi Gnudi; Adrian S Woolf
Journal:  Kidney Int       Date:  2013-02-27       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.